Assessing the Opioid Analgesic Risk Evaluation and Mitigation Strategy Program

Doris Auth^{1

2

3

4}, Judy Staffa^{3

4

5}, Cynthia LaCivita^{1

2

3

4}

Affiliations

¹ Division of Risk Management, US Food and Drug Administration, Silver Spring, Maryland.
² Office of Medication Error Prevention and Risk Management, US Food and Drug Administration, Silver Spring, Maryland.
³ Office of Surveillance and Epidemiology, US Food and Drug Administration, Silver Spring, Maryland.
⁴ Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
⁵ Public Health Initiatives, US Food and Drug Administration, Silver Spring.

Comment

Doris Auth et al. JAMA Intern Med. 2020.

. 2020 Jun 1;180(6):915-916.

doi: 10.1001/jamainternmed.2020.1260.

Doris Auth^{1

2

3

4}, Judy Staffa^{3

4

5}, Cynthia LaCivita^{1

2

3

4}

¹ Division of Risk Management, US Food and Drug Administration, Silver Spring, Maryland.
² Office of Medication Error Prevention and Risk Management, US Food and Drug Administration, Silver Spring, Maryland.
³ Office of Surveillance and Epidemiology, US Food and Drug Administration, Silver Spring, Maryland.
⁴ Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
⁵ Public Health Initiatives, US Food and Drug Administration, Silver Spring.

No abstract available

Comment in

Assessing the Opioid Analgesic Risk Evaluation and Mitigation Strategy Program-Reply.
Heyward J, Sharfstein J, Alexander GC. Heyward J, et al. JAMA Intern Med. 2020 Jun 1;180(6):916. doi: 10.1001/jamainternmed.2020.1112. JAMA Intern Med. 2020. PMID: 32364567 No abstract available.

Evaluation of the Extended-Release/Long-Acting Opioid Prescribing Risk Evaluation and Mitigation Strategy Program by the US Food and Drug Administration: A Review.
Heyward J, Olson L, Sharfstein JM, Stuart EA, Lurie P, Alexander GC. Heyward J, et al. JAMA Intern Med. 2020 Feb 1;180(2):301-309. doi: 10.1001/jamainternmed.2019.5459. JAMA Intern Med. 2020. PMID: 31886822 Review.